Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
ASH 2020: Dr. Jennifer Brown on combination duvelisib + venetoclax for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
ASH 2020: Dr. Meghan Thompson Interview – Venetoclax Retreatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen
This clinical trial introduces the concept of “synthetic lethality,” where multiple targeted agents are used at low dosages to block different pathways, and achieve the ability to kill cancer cells without the associated toxicities of using three drugs together at their usual dosages.
Foreword This article may be tough going for those without a deeper interest and knowledge about CLL cellular biology, but I hope by plowing through it, perhaps more than once, and watching the short educational videos, it will reward the
One click to our most popular content.
